University of Pennsylvania School of Medicine Jun 3 2026 A pioneering clinical trial has successfully enabled two patients with end-stage kidney disease to receive previously improbable kidney transplants. These individuals were considered among the most difficult in the nation to match with a compatible donor kidney due to harmful antibodies they had developed ("sensitized"). Researchers at the University of Pennsylvania (Penn) used chimeric antigen receptor (CAR) T-cell therapy, originally